Drugs / ZL-1218
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05859464 | Jul 2023 → Aug 2025 | cancer | Zai Lab | Terminated | No outcome recorded Stop: Business |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2024-07-15 | Zai Lab (Shanghai) Co., Ltd. | Results Zai Lab-Supported Study Published in Cell Provides New Insights with Potential to Improve Treatment of HRD-Positive Ovarian Cancers, Including Through Combination PARP Inhibitor and CCR8 Therapy zailaboratory.com ↗
This Zai Lab-supported study also showed that targeted clearance of infiltrating regulatory T cells (eTregs) using Zai Lab’s investigational CCR8 antibody, ZL-1218, significantly sensitized niraparib against HRD tumors, resulting in decreased tumor burden in pre-clinical models. |
| 2022-04-06 | Zai Lab (Shanghai) Co., Ltd. | Results Zai Lab to Present New Oncology Research at 2022 AACR Annual Meeting zailaboratory.com ↗
This oral presentation will highlight the discovery and development of this therapeutic, including the antitumor activity of ZL-1218 in an animal model, as a single agent and in combination with anti-PD-1. |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2024-08-27 | Zai Lab (Shanghai) Co., Ltd. | Zai Lab to Present Preliminary Data From Phase 1 Trial of ZL-1218, an Investigational Anti-CCR8 Antibody for the Treatment of Advanced Solid Tumors, at ESMO Congress 2024 zailaboratory.com ↗ |
| 2024-07-15 | Zai Lab (Shanghai) Co., Ltd. | Zai Lab-Supported Study Published in Cell Provides New Insights with Potential to Improve Treatment of HRD-Positive Ovarian Cancers, Including Through Combination PARP Inhibitor and CCR8 Therapy zailaboratory.com ↗ |
| 2022-04-06 | Zai Lab (Shanghai) Co., Ltd. | Zai Lab to Present New Oncology Research at 2022 AACR Annual Meeting zailaboratory.com ↗ |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ZL-1218 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05859464 ↗ |